Topically applicable composition containing solubilizates of lipophilic active substances

EP4466002A1Pending Publication Date: 2024-11-27SOLMIC BIOTECH GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023701635
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-05-13
Filing Date
2023-01-18
Publication Date
2024-11-27

AI Technical Summary

Technical Problem

Incorporating lipophilic active ingredients into topical products is challenging due to their sparing or insoluble nature in water, requiring time-consuming and costly processes using oil/oil mixtures or oil-water emulsions, which often result in an undesirably large volume increase to ensure homogeneous distribution.

Method used

The use of solubilisates, which are water-soluble micelles that encapsulate lipophilic substances, formed with emulsifiers and auxiliary substances like polysorbates and lecithins, allowing for stable, transparent, and water-soluble formulations that can replace or be added to the water phase, enabling homogeneous distribution without additional oils or emulsifiers.

Benefits of technology

This approach enhances the stability and absorption of active ingredients, providing improved skin care and therapeutic benefits while maintaining product stability against thermal, light, and chemical instability, suitable for cosmetic and pharmaceutical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000014_0001
    Figure IMGF000014_0001
  • Figure IMGF000014_0002
    Figure IMGF000014_0002
  • Figure IMGF000015_0001
    Figure IMGF000015_0001
Patent Text Reader

Abstract

The invention relates to a composition for topical application for medical or cosmetic purposes, which contains micellized extracts or micellized lipophilic active substances, in particular a composition that contains one or more solubilizates of lipophilic active substances on the basis of plant extracts, vegetable extracts, plant parts, phytotherapeutics, resins, vitamins, enzymes, proteins, algae, functional active substances and / or coenzymes, and mixtures and combinations thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Topically applicable composition containing solubilisates of lipophilic

[0002] Active ingredients

[0003] The invention relates to products for topical application comprising micellized extracts or micellized lipophilic active ingredients.

[0004] The incorporation of lipophilic and barely or insoluble active ingredients into final products poses a problem in that such active ingredients can only be incorporated into the final product for homogeneous distribution after a correspondingly time-consuming and costly process using oil / oil mixtures or oil-water emulsions. To incorporate a fat-soluble substance into the final product, it must be increased in volume by an undesirably large amount of oil to ensure optimal homogeneous distribution in the final product.

[0005] EP 1 768 497 B1 therefore describes the production of solubilisates of essential oils in order to be able to homogeneously incorporate substances that are insoluble or poorly soluble in water into end products.

[0006] EP 3 820 528 A1 describes solubilisates containing curcumin and at least one cannabinoid as an additional active ingredient for the production of capsules that act as food supplements or medicinal products.

[0007] WO 2021 / 037656 AA11 describes folic acid solubilisates used in food supplements and in wastewater treatment in septic tanks.

[0008] WO 2021 / 175763 A1 describes topical compositions containing cannabidiol encapsulated in niosomes. The niosomes consist of a hydrophobic bilayer and a hydrophilic core, meaning that fat-soluble substances are trapped between the bilayers, while water-soluble substances can be trapped inside the core.

[0009] WO 2021 / 030789 A1 relates to nanoencapsulated cannabidiol, which is used alone or in combination with naltrexone as a therapeutic agent for a number of diseases, such as pain conditions, Parkinson's disease, Alzheimer's disease, multiple sclerosis, Crohn's disease, and inflammation. The present invention is based on the object of providing products for topical application in which skin-care or healing active ingredients are formulated in such a way that they are well absorbed by the skin and lead to an improvement in the skin's appearance. Furthermore, the products should be characterized by good stability and durability.

[0010] This task is achieved in a product for topical application by containing solubilisates of lipophilic active ingredients

[0011] The invention thus relates to a product or composition for topical application containing solubilizates of lipophilic active ingredients as defined in claim 1. Thus, the solubilizates of the lipophilic active ingredients as defined in claim 1 are used to prepare products or compositions for topical application.

[0012] In the context of the application, the terms “article(s)”, “product(s)” and “composition(s)” are used synonymously.

[0013] The products contain solubilized active ingredients, which can be better processed into the product compared to pure isolates of the active ingredients and contribute to improved stability.

[0014] The solubilisates are water-soluble micelles that package lipophilic substances. Solubilisates are produced with the aim of enclosing lipophilic or insoluble or poorly water-soluble substances in such a way that they become water-soluble. A combination of emulsifier(s), fat-soluble active ingredients, and excipients forms stable, transparent, and water-soluble solubilisates. Preferred emulsifiers are polysorbates, poloxamer (Lutrol), gum arabic, sucrose stearate, DermofeelG 10 LW (70) MB, pasty Dermofeel® G 10 L, PEG-40 hydrogenated castor oil, lecithins, phospholipon, or D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS; also known as Vitamin E TPGS, tocopherol succinate (INN)). Poloxamers, for example, are suitable emulsifiers. Poloxamers are synthetic block copolymers of ethylene oxide and propylene oxide. Various liquid and semi-solid types exist, ranging from slightly soluble to highly soluble in water.Poloxamers are amphiphilic. For example, TPGS is another amphiphilic emulsifier that has a hydrophilic and a lipophilic molecular part. A polyethylene glycol moiety represents the polar head, and tocopherol succinate represents the lipophilic tail. This amphiphilic property leads to the self-association (micelle formation) of TPGS in water. Thus, fat-soluble components are enclosed within the interior of the micelle (lipophilic part) and dissolved in water through the water-soluble surface of the micelle. Possible excipients for improving the solubility of poorly water-soluble substances include ethanol (96%), polysorbate, and glycerol (anhydrous). For further details on the preparation of the solubilizates, please refer to the contents of the applicant's EP applications EP 3 675 825 (EP 18 738 297) and EP 3 675 824 (EP 18 737 274).

[0015] The active ingredients stably encapsulated in micelles are protected from thermal and light influences, and / or chemical instability (e.g., oxidation). The micelles are characterized by a hydrophobic core, in which the fat-soluble substances are enclosed, surrounded by a hydrophilic emulsifier layer.

[0016] In the manufacture of the products, the solubilizate is used as a single raw material. This has the advantage that it can be incorporated directly into the water phase or even completely replace the water phase. This allows not only oil-in-water (oil-in-water) but also water-in-oil (water-in-oil) and purely aqueous products to be produced without the addition of fat / oil or emulsifiers.

[0017] The water-soluble micelles distribute evenly throughout the aqueous solution, ensuring the homogeneity of the active ingredient in the product. Furthermore, hydrophobic active ingredients (extracts, lipophilic vitamins, etc.) encapsulated within the micelle are protected from external influences. This ensures improved stability of the active ingredient in the product.

[0018] Products for topical use are primarily cosmetic products, but also include medicinal or pharmaceutical compositions for application to the skin or mucous membranes. Examples include creams, lotions, milks, serums, gels, drops, emulsions, balms, fluids, shampoos, ointments, masks, foams, sprays, or facial toners. These products can be water-based or fat / oil-based. The products can be used for the care, cleansing, and / or therapeutic treatment of the skin or mucous membranes from head to toe, particularly the face. (Facial) masks, creams, and serums are preferred. Suitable active ingredients in the aforementioned products for topical use include lipophilic plant extracts, plant extracts, phytotherapeutics, algae, resins, vitamins, enzymes, proteins, functional active substances, and / or coenzymes, as well as mixtures and combinations thereof.All of the active ingredients mentioned have in common their positive effect on the skin, which includes both cosmetic use for the care and cleansing of all skin types, in particular for achieving an anti-aging effect, as well as therapeutic applications for skin diseases such as acne, erysipelas, urticaria, herpes, neurodermatitis, burns or psoriasis.

[0019] Examples of possible plant extracts or phytotherapeutics are evening primrose (Oenothera biennis), balloon vine (Cardiospermum halicacabum), wild pansy (Viola tricolor), horsetail (Equisetum arvense), German chamomile (Matricaria recutita), witch hazel (Hamamelis virginiana), Oregon grape (Mahonia aquifolium), birch (Betula pendula), ylang-ylang, Siberian ginseng (Eleutherococcus aureus), shea butter (Shea butter), cannabis plant (cannabinoids), turmeric (Curcuma langa), true lavender (Lavandula angustifolia), St. John's wort (Hypericum perforatum), Irish moss (Chondrus crispus), hops (Humulus lupulus), green tea (Camellia sinensis L.), centella (Centella asiatica), mallow (Malva sylvestris), meadowsweet (Filipendula ulmaria), marigold (Calendula officinalis L.) or red clover (Trifolium pratense).

[0020] In a preferred embodiment, the active ingredient is a cannabinoid, such as tetrahydrocannabiol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabichromevarin (CBCV), cannabigerol (CBG), cannabigerovarin (CBGV), cannabinol (CBN) or cannabicyclol.

[0021] Examples of possible algae are brown algae, red algae, green algae or blue-green algae.

[0022] Examples of possible vitamins are vitamin E, vitamin A, pro-vitamin A (beta-carotene), vitamin C, vitamin B3 (niacin), panthenol, provitamin B5 and vitamin B7 (biotin).

[0023] Examples of enzymes, proteins and coenzymes are lipases, cellulases, amylases, proteases, collagen, acetyl hexapeptide-8, pentapeptide-18 or ubiquinone-10 (Q10),

[0024] Examples of possible resins include frankincense, propolis, or myrrh. Other functional active ingredients include fruit acids (e.g., glycolic acid, lactic acid, malic acid, citric acid, tartaric acid), resveratrol, pterostilbene, astaxanthin, or substances that can interact with the functional pathways of hypoxia-induced factor (HIF), mTor, p53, GDNF, and GLUT1.

[0025] Particularly preferred solubilisates are: Micellar CBD (cannabidiol) -> Application: anti-wrinkle, anti-inflammatory Micellar Q10 or astaxanthin -> Application: anti-wrinkle, energy booster, antioxidant Micellar frankincense -> Application: antibacterial, anti-inflammatory Micellar propolis -> Application: antibacterial, anti-inflammatory Micellar Siberian ginseng, resveratrol, pterostilbene or HIF inhibitors -> Application: anti-aging, anti-wrinkle, antibacterial, anti-inflammatory

[0026] One or more other (water-soluble) substances with a positive effect on the skin can be added to the solubilisate or to the product for topical application, e.g., hyaluronic acid, aloe vera, centella extract, green tea extract, lactic acid, urea, or amino acids. In the case of a (face) mask, the (water-soluble) substances can be applied directly to the mask.

[0027] Furthermore, cosmetic or pharmaceutical excipients such as stabilizers, emulsifiers, preservatives, thickeners and / or binders may also be present.

[0028] To prevent oil and water from repelling each other, all emulsions require an emulsifier or solubilizer for their stability. The emulsifier is located at the interface between the two liquids and has both a polar and a non-polar molecular moiety. The polar ends of the emulsifier molecules attach to the water, while the non-polar ends attach to the oil molecules. Through this "docking," emulsifiers reduce the interfacial tension between the oil and water phases, thus stabilizing the emulsion. Suitable emulsifiers include Laureth-4, Ceteareth-15, PEG-8, Sucrose Stearate (E 473), Methyl Glucose Sequistearate, or Glyceryl Stearate. Stabilizers are often added to the emulsifiers. These coat the emulsified droplets with a protective film and ensure strong cohesion. Stabilizers include, for example, antioxidant vitamins, starch, dextrins, pectins, or proteins. Preferred stabilizers according to the invention (e.g.in face creams or lotions) are vitamin C or vitamin E, preferably in an amount of 0.2 - 1.8% by weight, most preferably 0.5 - 1.0% by weight.

[0029] Thickeners in cosmetic products ensure that the products always have an optimal consistency and increase viscosity. For example, they make lotions more viscous and creamier, making them easier to apply and providing a soft feel on the skin. These can be synthetic thickeners, such as liquid microplastic particles, or natural thickeners such as cellulose (E 460), xanthan gum (E 415), algin (E 400 - E 405), gellangum (E 418), pectin (E 440), or carrageenan (E 407). Although more expensive, natural thickeners are clearly preferred, as microplastics pose a clear environmental problem.

[0030] Preservatives protect cosmetic products from microbial spoilage and thus make an important contribution to consumer health. Water-containing products are particularly vulnerable because microorganisms can easily settle and multiply. Commonly used preservatives include parabens, alcohols (e.g., ethyl alcohol), or halogenated organic substances (e.g., benzoisothiazolinones, methylisothiazolinones, dichlorobenzyl alcohol, chlorhexidine).

[0031] Binders as ingredients in cosmetics ensure the desired cohesion of the products. They prevent solid and liquid components from separating. Typically, the amounts used are less than 2% of the total mass. Hydrophilic colloids (e.g., alginates), as well as carboxymethylcellulose, hydroxyethylcellulose, or xanthan gum are frequently used.

[0032] According to the invention, it was shown that the use of active ingredient solubilisates, compared to active ingredient isolates, allows for greater product stability for topical application. This applies in particular to face creams and facial serums, especially those containing CBD, propolis, Q10, or frankincense as active ingredients. The stability achieved by the active ingredient solubilisates can be further increased by the addition of stabilizers. However, if stabilizers are to be avoided in the cosmetic product, the solubilisates are clearly superior to the isolates, as the solubilisates already contribute to product stability without the need for additional stabilizers. When vitamin E is added at a higher concentration (e.g., 1%), a significant increase in the stability of the solubilisate can be observed compared to the stability of the isolate. This effect can still be observed, at least in creams with a higher fat content, with 1% vitamin E plus 1% vitamin C.

[0033] Due to the water-soluble properties of the solubilisates, they are ideal for use in cosmetic products where no fats or oils are desired, such as shampoos or masks.

[0034] Micellar protection protects the active ingredient in the inner core from light exposure, thus improving product stability during daily use.

[0035] In a preferred embodiment, the product to be applied to the skin is a (facial) mask for medical or cosmetic purposes containing micellized extracts or micellized lipophilic active ingredients.

[0036] In a preferred embodiment, a ready-to-use mask for cosmetic or medical purposes is provided, in which active ingredients for the care or healing treatment of the skin are prepared in such a way that they are well absorbed by the skin and lead to an improvement in the skin's appearance.

[0037] Such a mask is characterized in particular by

[0038] • that the mask contains solubilisates of lipophilic active ingredients

[0039] • that the mask is made of a flexible material

[0040] • that, if it covers the entire face, it contains perforated cutouts for, for example, the eyes and nose

[0041] To enable visual perception and unhindered breathing during treatment, the mask, if it covers the entire face, has perforated cutouts for the eyes and nose. This increases the user's well-being and allows individual adjustment to their needs. However, it is also possible for the mask to cover only parts of the face or neck. It is also possible for it to extend to the décolleté or cover other parts of the body. The mask is made of a flexible material. This can be a cellulose-containing material, a cotton-containing material, or a silk-containing material, as well as any combinations and mixtures thereof. Biocellulose is preferred, most preferably a material consisting of 90-98% water and 2-10% cellulose. In a preferred embodiment, masks consisting of 96% water and 4% cellulose are used.The term "biocellulose" refers to a smooth, roughened, or napped, flat fabric material used to make the face mask. The face mask can be made of cellulose or cellulose fleece, in one or more layers. In a preferred embodiment, the biocellulose mask is made from fermented bacteria. It is 100% compostable and, due to its composition, adheres well to the skin. Other preferred features of the biocellulose mask are:

[0042] - Fiber diameter 2-100 nm

[0043] - Fiber length 1-9 mm

[0044] - 3D structure

[0045] Alternatively, other flexible materials, such as film materials or materials made of cotton or silk fibers, can also be considered. The thickness of the layer(s) is flexible and depends on the fluid absorption required by the face mask for the specific application.

[0046] The cut of the mask can vary. The mask can cover the entire face, parts of the face, neck, décolleté, or other body parts. The terms "mask" and "face mask" are used interchangeably, and the term "face" is not limited to the face alone, but also includes the head and neck. It acts as a carrier for active substances that can penetrate the skin.

[0047] The masks according to the invention are preferably sterile and individually packaged. In a preferred embodiment, the mask (particularly a biocellulose mask) lies on a moistened nonwoven cloth and is covered with a perforated white plastic film. This allows the mask to be folded within the packaging and protects it from drying out. The packaging is preferably an aluminum film that can be printed, e.g., using CMYK printing. The face mask preferably has perforations for the eyes, nose, and possibly the mouth. Optional passages can be provided in the cheek area to accommodate the ears of the mask wearer. The face is divided into a forehead and chin area, as well as a central eye, nose, mouth, and cheek area. Corresponding areas of the face mask are assigned to these areas.Optional ear holes can be positioned to the sides of the face mask's central facial area. These holes enclose the ears and securely hold the face mask in place. This prevents the face mask from accidentally slipping off the face during treatment.

[0048] In a preferred embodiment of the mask, at least one recess is also provided for the nose. This recess is formed by a trapezoidal opening that can have a cutout or incision in the direction of the symmetry axis of the facial surface, extending up to the level of the eye area, to allow adaptation to different nose shapes. To create the nasal opening, the part of the mask enclosed by the perforation is placed on the nose, thus forming a passage for the nose.

[0049] The above-mentioned active ingredients, which are stably enclosed in micelles, are protected from thermal, light influences and / or chemical instability (e.g. oxidation).

[0050] Since the masks consist primarily of water, they can be loaded with micelles. The mask releases its moisture to the skin, along with the active ingredients. Tests have shown that the masks absorb at least 20%, preferably at least 50%, of the solubilizate used in production.

[0051] The following paragraphs describe the preferred embodiment of a (face) mask in more detail:

[0052] (1) Mask comprising one or more solubilisates of lipophilic active ingredients from plant extracts, plant extracts, plant parts, phytotherapeutics, resins, vitamins, enzymes, proteins, algae, functional active ingredients and / or coenzymes as well as mixtures and combinations thereof,

[0053] (a) wherein preferably the plant extracts, plant extracts or phytotherapeutics from evening primrose (Oenothera biennis), balloon vine (Cardiospermum halicacabum), wild pansy (Viola tricolor), horsetail (Equisetum arvense), true chamomile (Matricaria recutita), witch hazel (Hamamelis virginiana), Oregon grape (Mahonia aquifolium), birch (Betula pendula), ylang-ylang, Siberian ginseng (Eleutherococcus aureus), shea butter (Karite butter), cannabis plant (cannabinoids), turmeric (Curcuma langa), true lavender (Lavandula angustifolia), St. John's wort (Hypericum perforatum), Irish moss (Chondrus crispus), hops (Humulus lupulus), green tea (Camellia sinensis L.), centella (Centella asiatica), mallow (Malva sylvestris), meadowsweet (Filipendula ulmaria), marigold (Calendula officinalis L.), red clover (Trifolium pratense),

[0054] (b) wherein preferably the vitamins are vitamin E, vitamin A, pro-vitamin A (beta-carotene), vitamin C, vitamin B3 (niacin) and / or vitamin B7 (biotin),

[0055] (c) wherein the enzymes, proteins or coenzymes are preferably lipases, cellulases, amylases, proteases, collagen, acetyl hexapeptide-8, pentapeptide-18 and / or ubiquinone-10 (Q10),

[0056] (d) the resins preferably being frankincense, propolis or myrrh,

[0057] (e) wherein the functional active substances are preferably astaxanthin, resveratrol, pterostilbene, fruit acids or substances that can interact with the functional pathways of hypoxia-induced factor (HIF), mTor, p53, GDNF, GLUT1,

[0058] (f) wherein the solubilisates are a combination of emulsifier(s), fat-soluble active ingredients and excipients, wherein the emulsifier(s) is preferably selected from polysorbates, Lutrol and / or D-alpha-tocopheryl polyethylene glycol 1000 succinate and the excipients are preferably ethanol, polysorbate and / or glycerin.

[0059] (2) The mask is preferably made of biocellulose.

[0060] (3) The mask can be used for cosmetic purposes to care and cleanse any skin type, preferably achieving an anti-aging effect on the skin.

[0061] (4) The mask can also be used for therapeutic purposes in skin diseases, the skin disease preferably being acne, herpes, neurodermatitis, urticaria, erysipelas, burns or psoriasis.

[0062] (5) Furthermore, dermatological tests were conducted on the above-mentioned solubilized active ingredient-loaded masks. All masks are suitable for normal and sensitive skin. This means that the micelles are particularly gentle on the skin.

[0063] The invention is explained in more detail with reference to the figures:

[0064] Fig. 1 : CBD in acetone nitrile / water at daylight and RT

[0065] At room temperature and daylight, CBD in acetonitrile / water is reduced to approximately 3.7% of the initial concentration over a period of 281 days

[0066] Fig. 2: CBD in acetonitrile / water in the dark and 4°C

[0067] At room temperature and under exclusion of light, CBD in acetonitrile / water is reduced to 81.9% of the initial concentration over a period of 281 days

[0068] Fig. 3: CBD Poloxamer in daylight and RT

[0069] At room temperature and daylight, CBD in the solubilisate is reduced to 50.4% of the initial concentration over a period of 275 days

[0070] Fig. 4: CBD Poloxamer in the dark and 4 °C

[0071] At room temperature and under exclusion of light, the CBD concentration in the solubilisate remains stable over a period of 275 days

[0072] Fig. 5: Biocellulose face mask applied to a fabric made of

[0073] Nonwoven fabric rests

[0074] (1) Nonwoven layer

[0075] (2) Biocellulose

[0076] Fig. 6: Face mask in which the existing perforations for eyes,

[0077] Nose and mouth are shown

[0078] (3) Perforated plastic film The invention is illustrated by the following examples.

[0079] Example 1

[0080] Microbial stability of the solubilisate in the cosmetic product CBD gel

[0081] Composition of the gel with 1% CBD solubilisate

[0082] Production:

[0083] The appropriate amount of solubilizate is added to the aqueous phase. The pre-dissolved gel binders are added to the aqueous phase and stirred until the gel thickens. Additional active ingredients and preservatives are added.

[0084] Sample No.: COS011-AL-009

[0085] Ingredients:

[0086] Rose hydrolate, propylene glycol, water, betaine, Natrosol 250 HX, CBD solubilisate, lactic acid, potassium sorbate, xanthan gum

[0087] The gel, which consists of 80% aqueous phase and thus promotes the growth of germs, was subjected to the germ load test

[0088] Method:

[0089] To determine the initial bacterial count of the sample, 1 g of sample is diluted with Eugon LT SUP buffer, usually 1:10. To test for adequate preservation, the sample is inoculated with 1% of the respective bacterial suspension. The inoculated samples are stored at 22.5 ± 2.5 °C until the respective re-isolation time. After T7, T14, and T28, the number of the respective microorganism is determined using the surface spread method. If a recovery is performed, 1 g of sample is individually inoculated with the corresponding bacterial suspension at a ratio of 1:10. In the control assay, inoculation is carried out without the sample. Result:

[0090] 1. Test results:

[0091] Table 1 : Results of the conservation stress test

[0092] T7, T14, T28: Sampling times in days

[0093] Table 2: Germ reduction

[0094] T7, T14, T28: Sampling times in days The product meets criteria A and B in the antimicrobial protection test (test for adequate preservation) according to Annex B of DIN EN ISO 11930.

[0095] The following germs were used: 'Storage in master collection

[0096] Example 2:

[0097] Stability study microbiological investigation of propolis solubilisate

[0098] For the microbiological examination, propolis solubilisate, which was prepared from the ethanolic propolis extract, was stored in 50 ml brown glass bottles at

[0099] Room temperature and 40 °C climate cabinet. At day 0,

[0100] 90 and 180 samples were taken and examined for microbiological contamination. nn: not detected, NG: detection limit

[0101] Result:

[0102] No bacteria were detected in any of the samples tested, both at room temperature and at 40°C. Beyond the six-month period, microbiological tests were also conducted after 12 months. Due to the change in viscosity, the samples had to be diluted 1:10. Thus, the detection limit was 10, and even after this time, no bacteria could be detected in the solubilisate. Example 3:

[0103] Stability test - Aging test using the example of propolis solubilisate

[0104] For the aging test, samples of propolis solubilisate were stored at room temperature and 40°C. Samples were taken at the following time points: days 0, 30, 90, and 270. The following parameters were determined: color, turbidity, pH, density, and sediment. Since propolis is naturally darker in color, the samples were diluted 1:10 with water to detect turbidity and determine the pH.

[0105]

[0106] Example 4: Stability test UV light at room temperature

[0107] Method:

[0108] Cannabinoids are particularly sensitive to light, which induces the formation of specific oxidation products. Therefore, an HPLC experiment was conducted to investigate the difference in stability of CBD in an aqueous-organic solution (acetonitrile / water) compared to a 1 wt% CBD formulation with poloxamer. The samples were exposed to the natural daylight cycle for up to 281 days and measured at regular intervals. As a negative control, identically formulated samples were stored in the dark at 4°C.

[0109] Preparation of CBD Acetonitrile / Water Solution SQL031-TS-010 Stock Solution:

[0110] 109.9 mg of cannabidiol (purity 97%) was weighed into a 100 ml volumetric flask and filled with acetonitrile / H2O (60 / 40).

[0111] Processing of samples:

[0112] 100 μl sample + 900 μl acetonitrile (ACN) are transferred into a reaction tube and mixed thoroughly by vortexing, then transferred into an HPLC vial and measured on the HPLC.

[0113] Preparation of the Poloxamer formulation SQL031-46

[0114] 1% cannabidiol solubilisate with poloxamer is produced, corresponding to 10 mg / ml cannabidiol

[0115] Processing of the sample:

[0116] 100 μl of sample + 1900 μl of MeOH / acetonitrile (1:1) were extracted in a 50 ml tube for 1 h. The sample was then centrifuged, 100 μl of supernatant was removed, mixed with 900 μl of acetonitrile, and analyzed by HPLC.

[0117] HPLC measurement method:

[0118] Mobile phase: 90% ACN + 10% water + 0.1% formic acid, isocratic

[0119] Column oven temperature: 38°C

[0120] Sampler temperature: 38 °C

[0121] Flow: 0.5 ml / min

[0122] Running time: 15 min

[0123] Wavelength: 280 nm

[0124] HPLC chromatograms of the CBD solution with acetonitrile and water (1 mg / ml) and the CBD-poloxamer formulation (1 w / w-%) were recorded.

[0125] The poloxamer formulation demonstrates greater CBD stability compared to the aqueous-organic (ACN / H2O) solution. After more than 275 days of exposure to the natural daylight cycle at room temperature, the CBD concentration in the aqueous-organic solution decreased to 3.7% of the initial amount (the dark control to 80%). In comparison, the CBD concentration in the poloxamer formulation decreased to 50.4% (the dark control showed no reduction in CBD).

[0126] The results are shown in Figs. 1 - 4.

[0127] Example 5:

[0128] Stability of CBD solubilisate and CBD isolate in cosmetic products

[0129] Day cream with CBD isolate or CBD solubilisate

[0130] To compare the stability of the solubilisate in the cosmetic product, various day cream formulations (see table) were prepared with CBD solubilisate and CBD isolate. The main components of the cream remained the same, but the concentration of the additional stabilizers was varied, and their effect on the CBD content was observed.

[0131] Ingredients:

[0132] Water, Propylene Glycol, Jojoba Oil, Apricot Kernel Oil, Urea, Sodium Lactate, Shea Butter, Coconut, Beta-Glucan, Pectin, Cedar Nut Oil, Methyl Glucose Sesquistearate, Lanolin, Aloe Vera Powder, Lactic Acid, Cetyl Alcohol, Myristyl Myristate, Hyaluronic Acid, Xanthan Gum, Potassium Sorbate, CBD Isolate or CBD Solubilisate and / or Vitamin E, Vitamin C

[0133] The day cream consists of over 50% aqueous portion, 21% fatty phase, which already includes the emulsifier, 0.1% cannabidiol isolate or 1% cannabidiol solubilisate and other active ingredients.

[0134] The production of the day cream: After melting the fat phase, it is emulsified with the water phase and the other active ingredients are incorporated.

[0135] The difference in production lies in the addition of the respective cannabidiols. While the CBD isolate is melted in the fat phase, the CBD solubilisate is dissolved in the water phase.

[0136] Calculated CBD concentration in the final product

[0137] When 0.1% CBD isolate is added, the final concentration in the product is 0.1% cannabidiol.

[0138] When 1% CBD solubilisate (1% cannabidiol in the solubilisate) is added, the final concentration in the product is 0.01% cannabidiol.

[0139] The prepared samples were stored in a climate chamber at room temperature and 40 °C.

[0140] Processing of samples

[0141] Day cream with 0.1% CBD isolate

[0142] Weigh 200 mg of cream into a 10 ml flask, fill with THF (tetrahydrofuran), and vortex. After at least 12 hours of extraction, 200 μl of sample and 800 μl of acetonitrile (ACN) / H2O (70 / 30) are mixed in the reaction tube and centrifuged. The supernatant is transferred to an HPLC vial and measured.

[0143] Day cream with 1% solubilisate

[0144] Weigh 1000-2000 mg of cream into a 10 ml flask, fill with THF (tetrahydrofuran), and vortex. After at least 12 hours of extraction, 200 μl of sample and 800 μl of ACN / H2O (70 / 30) are mixed in a reaction tube and centrifuged. The supernatant is transferred to an HPLC vial and measured. Day cream with 21% fat content (O / W) and various stabilizer concentrations.

[0145] Day cream with CBD isolate, 0.1% CBD:

[0146] CBD CBD Isolate Without Vit E and Vit C COS013-AL-008

[0147] RT / 40°C day cream

[0148] CBD CBD isolate 0.2% Vit E + 0.2% Vit C COS013-AL-009

[0149] Room temperature / 40°C

[0150] Day cream

[0151] CBD CBD isolate 1%Vit E + 0.2 VIT C COS013-AL-010

[0152] Room temperature / 40°C

[0153] Day cream

[0154] CBD CBD Isolate 1% Vit E and 1% Vit C COS013-AL-011

[0155] Room temperature / 40°C

[0156] Day cream

[0157] Day cream: with CBD solubilisate, 0.01% CBD:

[0158] CBD CBD solubilisate without Vit E and Vit C COS013-AL-012

[0159] Room temperature / 40°C

[0160] Day cream

[0161] CBD CBD solubilisate 0.2% Vit E + 0.2%Vit C COS013-AL-013

[0162] Room temperature / 40°C

[0163] Day cream

[0164] CBD CBD solubilisate 1%Vit E + 0.2% VIT C COS013-AL-014

[0165] Room temperature / 40°C

[0166] Day cream

[0167] CBD CBD solubilisate 1%Vit E + 1% Vit C COS013-AL-015

[0168] Room temperature / 40°C

[0169] Day cream

[0170] Result:

[0171] Explanation of the table: "tO7" initial7"t9O": During the manufacturing process, minimal weighing errors, evaporation, and losses due to agitation can lead to deviations in the CBD concentration in the final product. The smaller the batch, the greater the deviation. Therefore, the actual concentration in the final product must be determined on day 0. This initial value serves as the starting value. On day 0, the deviation from the target value is determined. On day 90, the deviation from the initial value is calculated. Comparison of day cream with CBD isolate and CBD solubilizate (only the 40°C samples are compared)

[0172] The measurement shows that without the addition of stabilizers (vitamin E and vitamin C), the CBD in the micelle (COS013-AL-012) has a slightly higher stability after 90 days than the similar day cream with CBD isolate (COS013-AL-008).

[0173] When using stabilizers, ie vitamin E and C in equivalent low amounts (e.g. 0.2%), approximately equal stability of the two active ingredients is observed in both formulations (CGS013-AL-013 / COS013-AL-009).

[0174] When vitamin E was added at a higher concentration (1%), a significant increase in the stability of the solubilizate was observed compared to the stability of the isolate (COS013-AL-014 / COS013-AL-010). This effect was also observed in the second measurement with 1% vitamin E plus 1% vitamin C (CGS013-AL-015 / COS013-AL-011).

[0175] CBD serum, 5% fat content

[0176] Serum with CBD isolate or CBD solubilisate

[0177] To compare the stability of the solubilisate in cosmetic products, various serum formulations (see table) were prepared with CBD solubilisate and CBD isolate. The main components of the serums remained the same, but the concentration of the additional stabilizers was varied, and their effect on the CBD content was observed. Ingredients:

[0178] Rose hydrolate, water, propylene, jojoba oil, lecithin, betaine, hydroxyethylcellulose, myristyl myristate, potassium sorbate, xanthan gum, CBD isolate or CBD solubilisate 1% and / or vitamin C, vitamin E

[0179] The serum consists of 70% aqueous phase, 5% fatty phase, emulsifier, 0.1% cannabidiol isolate or 1% cannabidiol solubilisate and other active ingredients.

[0180] Production of the CBD serum

[0181] After melting the fat phase, it is emulsified with the water phase and the other active ingredients are incorporated.

[0182] The difference in production lies in the addition of the respective cannabidiols. While the CBD isolate is melted in the fat phase, the CBD solubilisate is dissolved in the water phase.

[0183] Calculated CBD concentration in the final product

[0184] When 0.1% CBD isolate is added, the final concentration in the product is 0.1% cannabidiol.

[0185] When 1% CBD solubilisate (1% cannabidiol in the solubilisate) is added, the final concentration in the product is 0.01% cannabidiol.

[0186] The prepared samples were stored in a climate chamber at room temperature and 40 °C.

[0187] Processing of samples

[0188] Serum with 0.1% CBD isolate

[0189] 800 mg of serum is weighed into a 10 ml flask, filled with THF (tetrahydrofuran), and vortexed. After at least 12 hours of extraction, 200 μl of sample and 800 μl of acetonitrile (ACN) / H2O (70 / 30) are mixed in the reaction tube and centrifuged. The supernatant is transferred to an HPLC tube and measured.

[0190] Serum with 1% solubilisate

[0191] 200-400 mg of serum are weighed into a 2 ml flask, filled with THF (tetrahydrofuran) and vortexed. After at least 12 hours of extraction, 200 μl of samples and 800 μl of ACN / H2O (70 / 30) are mixed in the reaction tube and centrifuged.

[0192] Supernatant is transferred to an HPLC tube and measured

[0193] NA: not measured

[0194] It was found that in emulsions containing CBD isolate with a 5% fat content, the addition of vitamin C compromises the stability of the formulation. The higher the vitamin C content, the more severe the emulsion separation. This separation process could only be reduced with a high concentration of vitamin E (1%) in the serum.

[0195] In contrast, no moderate or severe emulsion separation was observed for formulations containing CBD solubilisate in serum over a three-month period at 40 degrees Celsius. Therefore, it can be concluded that the formulations containing solubilisates are more stable, regardless of stabilizers and their concentration, than those containing CBD isolate. Example 6: Loading of masks

[0196] The cut mask is placed in an airtight package and loaded with the essence containing solubilized ubiquinone at the filling machine. The machine dispenses a specific amount of 15–45 g of essence into the finished package. By repeatedly pressing the side of the package, the essence is evenly distributed so that the mask is completely coated with the essence. The package is then sealed. After storage for 3–7 days, the mask is saturated with the essence. Essence production:

[0197] Further features of the biocellulose mask

[0198] - Fiber diameter 2-100 nm

[0199] - Fiber length 1-9 mm

[0200] - 3D structure

[0201] Example 7: Measurement of solubilisates from masks with regard to stability

[0202] The solubilisates of various active ingredients were extracted from corresponding masks and measured for their stability.

[0203] To investigate the stability of the solubilizates, the ingredients in the mask and essence were determined and analyzed over a period of three months at room temperature and 40°C. Q10, Siberian ginseng, propolis, and frankincense solubilizates were analyzed. During the analytical method development, it was determined that at least 50% of the raw material concentration used in the masks can be recovered. This can be explained by diffusion. Before the biocellulose mask is placed in the essence, i.e., the prefabricated mask, which contains up to 98% of its total weight in water, the molar concentration is equalized. The mask absorbs at least 50% of the active ingredient. The determined initial molar concentration is the starting value of the zero measurement and represents 100% of the initial value. Q10 Biocellulose Mask Processing

[0204] The mask, immersed in 3% essence solution, was cut into approximately 1 g pieces and placed in a tube containing approximately 4 g of tetrahydrofuran (THF). The sample material was vortexed in the tube during the extraction period. The total weight of the mask sample and that of the solvent were added and recorded.

[0205] A sample of 100 μl of the solution containing the sample was taken and mixed with 900 μl of methanol / 1-propanol (50 / 50 v / v). The sample was then analyzed using HPLC-UV.

[0206] The concentration in the extracted solution was determined using a 6-point calibration curve ranging from 1-100 pg / ml. Quality control samples, which must meet a predefined value (3 pg / ml, 50 pg / ml, 80 pg / ml) during a run, served as controls. After measuring the extraction, approximately 50% of the raw material used was recovered. The essence was also measured. The determined and validated value was used as the initial value.

[0207] Siberian Ginseng Biocellulose Mask Reprocessing

[0208] The mask, immersed in a 3% essence solution, was cut into approximately 1 g pieces and placed in a tube containing approximately 4 g of water (H2O). The sample material was vortexed in the tube during the extraction period. The total weight of the mask sample and that of the solvent were added and recorded.

[0209] 200 μl of the solution containing the sample was taken and mixed with 800 μl of methanol / water (50 / 50 v / v). The sample was then analyzed using HPLC-UV. Ferulic acid was used as the reference standard, as described in Ph.Eur 9.0 / 1419. This allowed the eleutheroside B content to be calculated. For comparison, the Siberian ginseng solubilisate used was diluted to 3%, analogous to the mask essence, to determine the eleutheroside B content. Based on the value determined in the diluted solubilisate, the deviation in the essence and the mask could be determined. 57% of the active ingredient used was recovered. This value was used as the initial value.

[0210] Frankincense Bioceilulose Mask Reconditioning

[0211] The mask, immersed in 3% essence solution, was cut into approximately 1 g pieces and placed in a tube containing approximately 4 g of tetrahydrofuran (THF). The sample material was vortexed in the tube during the extraction period. The total weight of the mask sample and that of the solvent were added and recorded.

[0212] 1000 μl of the solution containing the sample was taken and first centrifuged and then measured using HPLC-UV.

[0213] Using a 4-point calibration curve between 10-200 pg / ml, boswellic acid (AKBA) was used as a reference standard to determine the concentration in the extracted solution. The essence and the solubilizate used were also measured. After measuring the extraction, approximately 50% of the raw material used was recovered. The determined and validated value was used as the initial value.

[0214] Propolis Biocelilose Mask Reprocessing

[0215] The mask, immersed in a 3% essence solution, was cut into approximately 1 g pieces and placed in a tube containing approximately 4 g of water / acetonitrile (90 / 10 v / v). The sample material was vortexed in the tube during the extraction period. The total weight of the mask sample and that of the solvent were added and recorded.

[0216] 1000 μl of the solution containing the sample was taken and first centrifuged and then measured using HPLC-UV.

[0217] Using a 4-point calibration curve between 2-20 pg / ml of chrysin as a reference standard, the concentration in the extracted solution was determined. The essence and the solubilizate used were also measured. After measuring the extraction, approximately 66% of the raw material used was recovered. The determined and validated value was used as the initial value.

[0218] The measurement data of the solubilisates in the masks are as follows: The measurement data show that the concentration of raw materials used must be taken into account, as equilibration occurs due to diffusion. The solubilizates in the masks remain stable, and the liquid surrounding the masks (essence) containing the solubilizates also remains stable. Assuming storage at 40 °C, the stability of the solubilizates in the masks is guaranteed for at least 12 months.

Claims

Patent claims 1) Topically applicable composition selected from a cream, lotion, milk, serum, gel, drops, emulsion, balm, fluid, ointment, mask and / or foam, wherein the composition comprises one or more micellar solubilisates of lipophilic active ingredients from plant extracts, plant parts, phytotherapeutics, resins, enzymes, vitamins, proteins, algae, functional active ingredients and / or coenzymes, as well as mixtures and combinations thereof. 2) Composition according to claim 1, wherein the plant extracts, plant extracts or phytotherapeutic agents are derived from evening primrose (Oenothera biennis), balloon vine (Cardiospermum halicacabum), wild pansy (Viola tricolor), horsetail (Equisetum arvense), German chamomile (Matricaria recutita), witch hazel (Hamamelis virginiana), Oregon grape (Mahonia aquifolium), birch (Betula pendula), ylang-ylang, Siberian ginseng (Eleutherococcus), shea butter (Karitebutter), cannabis plant (cannabinoids), turmeric (Curcuma langa), English lavender (Lavandula angustifolia), St. John's wort (Hypericum perforatum), Irish moss (Chondrus crispus), hops (Humulus lupulus), green tea (Camellia sinensis L.), and centella (Centella). asiatica), Mallow (Malva sylvestris), Meadowsweet (Filipendula ulmaria), Marigold (Calendula officinalis L.), Red clover (Trifolium pratense) originate. 3) Composition according to claim 1 or 2, wherein the active ingredient is a cannabinoid, preferably tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabichromevarin (CBCV), cannabigerol (CBG), cannabigerovarin (CBGV), cannabinol (CBN) or cannabicyclol. 4) Composition according to claim 1, wherein the enzymes, proteins or coenzymes are lipases, cellulases, amylases, proteases, collagen, acetyl hexapeptide-8, pentapeptide-18 and / or ubiquinone-10 (Q10). 5) Composition according to claim 1, wherein the resins are frankincense, propolis or myrrh. 6) Composition according to claim 1, wherein the functional active ingredients are astaxanthin, resveratrol, pterostilbenes, fruit acids or substances combined with the functional pathways of hypoxia-induced factor (HIF), mTor, p53, GDNF, GLUT1 can interact. 7) Composition according to any one of claims 1-6, wherein the solubilisates are a combination of emulsifier(s), fat-soluble active ingredients and excipients. 8) Composition according to claim 7, wherein the emulsifier is selected from polysorbates, Lutrol and / or D-alpha-tocopheryl polyethylene glycol 1000 succinate. 9) Composition according to claim 7 or 8, wherein the excipients are ethanol, polysorbate and / or glycerin. 10) Composition according to any one of claims 1-9, wherein it additionally contains cosmetic or pharmaceutical excipients, preferably emulsifiers, stabilizers, preservatives, thickeners and / or binders. 11) Composition according to claim 10, wherein the stabilizer is vitamin C or vitamin D. 12) Use of the composition according to any one of claims 1-11 for cosmetic purposes for the care and / or cleansing of any skin type. 13) Composition according to any one of claims 1-11 for use in a method for treating skin diseases. 14) Composition for use according to claim 13, wherein the skin disease is acne, herpes, neurodermatitis, urticaria, erysipelas, burns or psoriasis.